Clinical Trial Detail

NCT ID NCT03735290
Title A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer (ILIAD)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Immunicum AB
Indications

gastric adenocarcinoma

lung non-small cell carcinoma

gastroesophageal junction adenocarcinoma

head and neck squamous cell carcinoma

Therapies

Pembrolizumab

Intuvax + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.